Teva Pharmaceutical Industries (NYSE:TEVA) Sees Significantly Higher Trading Volume


Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is trading considerably higher today, now up $3.13 at $18.63 - a 20 percent gain. The health-care sector remains susceptible to regulatory risk, warned one brokerage, which recommended investors pick individual health-care stocks rather than seek broad exposure to the sector.

Several other equities research analysts have also recently weighed in on the company. Schultz inherits hard challenges at Teva, including a potential generic Copaxone launch, high financial leverage, and competitive pressures in the generics industry. On August 16 the stock rating was downgraded from "Buy" to "Neutral" in a statement from Citigroup. Goldman Sachs maintained it with "Buy" rating and $80 target in Monday, August 10 report. Credit Suisse Group reiterated a "buy" rating and issued a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, May 17th. More interesting news about Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) were released by: and their article: "Time to Start Buying Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock?" published on August 15, 2017 as well as's news article titled: "Why Transocean LTD (RIG), Teva Pharmaceutical Industries Ltd (ADR) (TEVA) and ..." with publication date: August 16, 2017. SELL rating has been given by 0 analyst (s) and 1 analyst (s) given BUY rating to the stock. The stock has a consensus rating of "Hold" and an average target price of $33.32. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned "Outperform" rating by Oppenheimer on Thursday, July 14. The company has a 50-day moving average of $20.66 and a 200 day moving average of $29.07. "In addition, we are on course to hit our target of generating at least $2 billion from the sale of non-core assets, which we will use to strengthen Teva's balance sheet". The company has lost about 57 percent of market value this year before today's rally. Annual EPS Growth of past 5 years is -53.00%. The business had revenue of $5.69 billion for the quarter, compared to analysts' expectations of $5.72 billion. Therefore 14% are positive. The firm's revenue for the quarter was up 12.9% compared to the same quarter previous year. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and global trademark & copyright laws.

Teva shares were up 21.14 percent, or $3.27, to $18.76 in late morning trading.

More news: Destiny 2 pulls in 1.2M concurrent online players

In August, Teva announced it would cut 7,000 jobs by year's end, close or sell 15 factories, and quit operations in 45 countries. Teva took a $6.1 billion write-down on that unit and posted a quarterly net loss of $6.04 billion. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company's stock worth $116,000 after acquiring an additional 261 shares in the last quarter.

Middlefield Banc a bank holding company. Analyst IMS Investment Management Services Ltd. lifted its stake in shares of Teva Pharmaceutical Industries Limited by 8.4% in the second quarter.